---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-196506"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:07:15.758860+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Phathom Q2 revenue $7.3M, prescriptions up 184%; VOQUEZNA gets FDA approval for Non-Erosive GERD

## Summary
- Net revenues $7.3M in Q2 2024 vs $1.9M in Q1 2024; no Q2 2023 revenue due to launch in late 2023.
- Over 122,000 cumulative prescriptions written (184% increase from 43,000); over 60,000 filled (240% from 17,500).
- FDA approved VOQUEZNA 10mg for Non-Erosive GERD on July 18; commercial coverage now >116M lives (77% of US commercial).
- Net loss $91.4M; non-GAAP adjusted net loss $73.3M; SG&A rose to $75.9M on launch commercialization.

## SEC filing metadata
- accession: 0001193125-24-196506
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312524196506/0001193125-24-196506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312524196506/d834335d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-196506
- JSON: https://secwatch.observer/filing/0001193125-24-196506.json
- Plain text: https://secwatch.observer/filing/0001193125-24-196506.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.